Literature DB >> 26216822

Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies.

Gino In1, Tanya Dorff2.   

Abstract

The rate of diagnosis of germ cell tumors has remained fairly constant. By the International Germ Cell Cancer Consensus Classification, roughly 60% of all metastatic germ cell tumors are classified as good risk. This group of patients has an excellent prognosis, with greater than 90% expectation of cure. Treatment standards have not changed much in recent years. This article focuses on key concepts in the development of the currently accepted first-line regimens and addresses some evolving areas of interest, if not controversy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bleomycin; Cisplatin; Etoposide; Germ cell tumor

Mesh：

Substances：

Year:  2015        PMID： 26216822      PMCID： PMC9484323          DOI： 10.1016/j.ucl.2015.04.009

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.766


  100 in total

1.  Sexual dysfunction after treatment for testicular cancer: a systematic review.

Authors:  I Nazareth; J Lewin; M King
Journal:  J Psychosom Res       Date:  2001-12       Impact factor: 3.006

2.  Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.

Authors:  J M O'Sullivan; R A Huddart; A R Norman; J Nicholls; D P Dearnaley; A Horwich
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

3.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Authors:  S D Fosså; S B Kaye; G M Mead; M Cullen; R de Wit; I Bodrogi; C J van Groeningen; P H De Mulder; S Stenning; E Lallemand; L De Prijck; L Collette
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

4.  Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold.

Authors:  S W Hansen; N Olsen
Journal:  J Clin Oncol       Date:  1989-07       Impact factor: 44.544

5.  A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

Authors:  F Cavalli; O Klepp; J Renard; M Röhrt; P Alberto
Journal:  Eur J Cancer       Date:  1981-02       Impact factor: 9.162

6.  Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.

Authors:  J Pedersen-Bjergaard; G Daugaard; S W Hansen; P Philip; S O Larsen; M Rørth
Journal:  Lancet       Date:  1991-08-10       Impact factor: 79.321

7.  Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.

Authors:  Peter Albers; Roswitha Siener; Susanne Krege; Hans-Uwe Schmelz; Klaus-Peter Dieckmann; Axel Heidenreich; Peter Kwasny; Maik Pechoel; Jan Lehmann; Sabine Kliesch; Kai-Uwe Köhrmann; Rolf Fimmers; Lothar Weissbach; Volker Loy; Christian Wittekind; Michael Hartmann
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

8.  Low-dose bleomycin lung.

Authors:  K S Wilson; A Worth; A G Richards; H S Ford
Journal:  Med Pediatr Oncol       Date:  1982

9.  Late relapse of testicular cancer.

Authors:  J Baniel; R S Foster; R Gonin; J E Messemer; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer.

Authors:  P M Petersen; S W Hansen; A Giwercman; M Rørth; N E Skakkebaek
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.